US Biotechnology *VIDEO* Enveda Biosciences: Multiple Key Clinical Readouts in the Next 12-18mos + Oral Presentation at EADV in Oct

研报英文原文证据摘录

US Biotechnology *VIDEO* Enveda Biosciences: Multiple Key Clinical Readouts in the Next 12-18mos + Oral Presentation at EADV in Oct

Global Research

23 July 2026ab

US Biotechnology Equities

Americas*VIDEO* Enveda Biosciences: Multiple Key

Clinical Readouts in the Next 12-18mos + Oral Biotechnology

Presentation at EADV in Oct MichaelAnalystYee

michael.yee@ubs.com

+1-305-536 9101

Figure 1: Watch the Video Interview BelowWatch Dina Elmonshed

Analyst

dina.elmonshed@ubs.com

+1-212-649 8276

Kyle Yang, CFA

Associate Analyst

kyle.yang@ubs.com

+1-212-713 1458

Matthew Hagood

matthew.hagood@ubs.com

+1-212-713 1107

Madeleine Lee

madeleine.lee@ubs.com

+1-212-713 1476

Roy Zawadzki, PhD

roy.zawadzki@ubs.com

+1-212-713 1139Source:UBS Research Nijat Mammadov, CFA

*CLICK HERE TO SEE THE FIRESIDE CHAT* nijat.mammadov@ubs.com

+1-212-821 3089

Enveda recently shared the Phase IB results for its first in class oral small molecule ENV-

294 in atopic dermatitis at the AAD innovation academy and will present the full dataset

at the EADV conference in early Oct in Vienna. We hosted Enveda's founder and CEO,

Viswa Colluru, recently at our Private Biotech Summit in NYC, and learned more about

Enveda's AI-powered, nature-inspired drug discovery platform, as well as its two key

lead programs: ENV-294, a novel small molecule for AD and asthma, and a novel once-

daily oral therapy for cardiometabolic health management. The company sees

significant value creation potential over the next 12–18 months, with important data

readouts expected across the pipeline.

Lead program ENV-294 has demonstrated promising early clinical data… which

compares favorably against other oral comps for AD (see our previous note HERE). (1)

Enveda reported strong EASI responder rates at Day 42. 100% of patients achieved